In Situ Hybridization Market Size & Share, by Technology (FISH, CISH); Product (Instruments, Kits & Probes, Software, Services); Probe (DNA, RNA); End-User (Research & Diagnostic Laboratories, CROs, Academic Institutes, Pharmaceutical & Biotechnological Companies); Application (Cancer, Cytogenetics, Developmental Biology, Infectious Diseases, Neuroscience) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5338
  • Published Date: Oct 20, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

In Situ Hybridization Market size is poised to reach USD 4 Billion by the end of 2036, growing at a CAGR of 12% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of in situ hybridization was USD 2 Billion. The reason behind the growth is due to the rising incidence of cancer across the globe. Fluorescence in situ hybridization also known as FISH scans cells for alterations in genes can aid in cancer diagnosis and can be used to track treatment response and illness remission. In 2040, there will likely be more than 28 million new instances of cancer worldwide.

The growing technological advancements in In-vitro diagnostics (IVD) are believed to fuel the market growth. For instance, Artificial intelligence (AI) technology integration in oncology-based in vitro diagnostic (IVD) technologies has the potential to significantly enhance healthcare decisions by identifying disease signatures that can aid in early detection and treatment, and by identifying central nervous system (CNS) cancers by predicting which therapy responses will be most successful using patient samples.

/admin/upload_images/In Situ Hybridization Market.webp
Get more information on this report: Request Free Sample PDF

In Situ Hybridization Market: Key Insights

Base Year


Forecast Year




Base Year Market Size (2023)

~ USD 2 Billion

Forecast Year Market Size (2036)

~ USD 4 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

In Situ Hybridization Sector: Growth Drivers and Challenges


Growth Drivers

  • Presence of High-Quality Molecular Tests – In situ hybridization (ISH), a very potent molecular technique, that is used to diagnose certain chromosomal abnormalities by assessing the presence or absence of fluorescence-labeled signals in interphase or metaphase nuclei or chromosomes.
  • Growing Elderly Population- The elderly population is more prone to age-related disorders such as cancer and other neurodegenerative diseases which is expected to drive the demand for in situ hybridization as this technology is widely used to study cancer, infectious diseases, and developmental biology, and can be used to detect cryptic chromosomal abnormalities and small aberrant clones.

According to the World Health Organization (WHO), the number of individuals in the world who are 60 or older will increase to 2.1 billion by 2050.

  • Spiking Prevalence of Infectious Diseases- In situ hybridization (ISH) is a potent method for detecting specific RNAs and was created with the technology of molecular genetics to identify infectious pathogens.
  • Increasing Trend of Minimally Invasive Procedures- The in situ hybridization (FISH) assay is a non-invasive method used to diagnose and track urothelial carcinoma (UC) in the upper urinary tract (UUT) and the test also looks for chromosomal alterations.
  • Rising Advancements in Digital Pathology- Digital pathology is a branch of pathology that, will be used as a tool for FISH imaging in both clinical and research settings rather than live microscopy slides in the future.


  • Exorbitant Cost of In Situ Hybridization Assays- In situ hybridization is expensive owing to the use of the high cost of the specialized reagents, as well as the high cost of probes. Besides this, the technology is labor-intensive and consequently expensive for labs to utilize as it requires trained medical professionals and expertise. 
  • Lack of Skilled Professionals to Carryout In Situ Hybridization Diagnosis
  • Growing Preference for Alternative Molecular Technologies Including Polymerase Chain Reaction (PCR)

In Situ Hybridization Segmentation

Technology (Fluorescent In Situ Hybridization (FISH), Chromogenic In Situ Hybridization (CISH))

The fluorescent In situ hybridization (FISH) segment in the in situ hybridization market is estimated to gain a robust revenue share of 55% in the coming years owing to the rising incidence of genetic diseases. It is expected that rising cases of stillbirths, and frequent miscarriages are all signs leading to a hereditary condition that is characterized by one or more anomalies in the genome is referred to as a genetic condition. 

Lately, the majority of in situ hybridization procedures employ fluorescent probes which is a laboratory technique used to detect DNA sequences, and is applied to detect genetic abnormalities, and diagnose congenital diseases. For instance, in industrialized nations, genetic illnesses and congenital anomalies account for over 25% of pediatric hospital admissions, affect more than 4% of all live births, and account for roughly 49% of all infant fatalities.

Additionally, the chromogenic In situ hybridization (CISH) segment is anticipated to garner significant market share. Chromogenic in situ hybridization (CISH), is a cytogenetic method for determining gene amplification using a peroxidase-based chromogenic reaction that is growing in popularity as a useful, affordable, and legitimate alternative to fluorescent in situ hybridization when testing for gene alteration, particularly in centers that focus primarily on immunohistochemistry (IHC).

Probe (DNA, RNA)

The DNA segment in the in situ hybridization market is set to garner a notable share shortly. In situ hybridization uses many different kinds of probes; including a DNA probe that is a popular technique for mapping sequences to certain chromosomal regions, and can be used to hybridize to a sample's known target DNA or mRNA sequence. Besides this, the probes can be utilized to find the location of the mRNA and are used to enzymatically integrate nucleotides with amine modifications.

End-User (Research & Diagnostic Laboratories, CROs, Academic Institutes, Pharmaceutical & Biotechnological Companies)

The research & diagnostic laboratories segment in the in situ hybridization market is poised to garner a significant share by the year 2036. In situ, hybridization is a laboratory method for recognizing certain mRNA species within individual cells in tissue sections and is widely being utilized for scientific purposes, including clinical cytogenetics, gene mapping, tumor biology, and investigations of chromosome evolution.

Application (Cancer, Cytogenetics, Developmental Biology, Infectious Diseases, Neuroscience)

The cancer segment is anticipated to gain a notable market share during the forecast timeframe. In Situ, the Hybridization test is effective for detecting some forms of the disease and can provide information about the genetic makeup of cancer. Besides this, this method can more accurately predict the prognosis and course of specific cancers, such as leukemias, lymphomas, melanoma, bladder cancer, and others, and can be employed in research to identify other diseases, and lowering the risk of birth deformities through in vitro fertilization (IVF).

Our in-depth analysis of the global in situ hybridization market includes the following segments:


  • Fluorescent In Situ Hybridization (FISH)
  • Chromogenic In Situ Hybridization (CISH)


  • Instruments
  •  Kits & Probes
  • Software, Services


  • DNA
  • RNA


  • Cancer
  • Cytogenetics
  •  Developmental Biology
  • Infectious Diseases
  • Neuroscience


  • Research & Diagnostic Laboratories
  • CROs
  •  Academic Institutes
  • Pharmaceutical & Biotechnological Companies

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

In Situ Hybridization Industry - Regional Synopsis

North American Market Forecast

In situ hybridization market in North America is predicted to account for the largest share of 45% by 2036 impelled by the increasing spending in healthcare. This has led to the development of advanced diagnostic technologies including In Situ Hybridization which is expected to improve the accessibility to these services for people in the region. According to estimates, spending on health care in the United States increased by more than 2% in 2021 to around USD 4 trillion.

APAC Market Statistics

The APAC in situ hybridization market is estimated to be the second largest, during the forecast timeframe led by rising initiatives to improve the healthcare system. For instance, several efforts have been initiated by the government of India to increase access to healthcare such as Ayushman Bharat, which seeks to holistically treat health at primary, secondary, and tertiary levels and aims to meet the healthcare needs of more than 70% of people throughout their lifetime. As a result, there is a growing demand for diagnostic tools such as In situ hybridization as more people are likely to emphasize early diagnosis of several diseases.

Research Nester
/admin/upload_images/In Situ Hybridization Market size.webp
Get more information on this report: Request Free Sample PDF

Companies Dominating the In Situ Hybridization Landscape

    • Thermo Fisher Scientific Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Abbott
    • PerkinElmer, Inc.
    • Leica Biosystems Nussloch GmbH
    • F. Hoffman-La Roche Limited
    • NeoGenomics Laboratories, Inc.
    • Advanced Cell Diagnostics, Inc.
    • BioView
    • Agilent Technologies, Inc.
    • Merck KGaA
    • Bio-Rad Laboratories, Inc.
    • Oxford Gene Technology IP Limited
    • Bio-Techne Corporation


In The News

  • Bio-Techne Corporation launched new DNAscope Assays and expanded the RNAscope technology which is an advanced in situ hybridization (ISH) assay to allow for the quick and versatile creation of probes for any DNA target, as well as the visualization of targets in formalin-fixed paraffin-embedded (FFPE) tissues. Furthermore, DNAscope offers advantages over current commercial FISH methods and permits scientists to see and count gene copy number changes and gene rearrangements/fusions in tissues with spatial and morphological contexts.
  • Leica Biosystems Nussloch GmbH together with Bio-Techne introduced the CE-IVD marked RNAscope In Situ Hybridization Detection Kit to assist pathologists in gaining access to the top software to help their diagnostics labs and allow greater target sensitivity and specificity compared to conventional ISH techniques.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 5338
  • Published Date: Oct 20, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The rising incidence of cancer across the globe and the growing technological advancements in In-vitro diagnostics (IVD) are the major factors driving the growth of the market.

The market size of In Situ Hybridization is anticipated to attain a CAGR of 12% over the forecast period, i.e., 2024 – 2036.

The major players in the market are Thermo Fisher Scientific Inc., Abbott, PerkinElmer, Inc., Leica Biosystems Nussloch GmbH, F. Hoffman-La Roche Limited, NeoGenomics Laboratories, Inc., Advanced Cell Diagnostics, Inc., BioView, Agilent Technologies, Inc., Merck KGaA, Bio-Rad Laboratories, Inc., Oxford Gene Technology IP Limited, and others.

The fluorescent In situ hybridization (FISH) segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
In Situ Hybridization Market Report Scope

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying